News
The latest updates on our research projects and fundraising achievements.Duchenne Care UK podcast series launched
On World Duchenne Awareness Day 2026, we are pleased to share the launch of the Duchenne Care UK podcast series. The series is based on the Duchenne Care UK Patient and Family Guides and break down information into accessible, short episodes …
Duchenne Care UK orthopaedic guideline recognised by NICE
We are pleased to share that NICE has recognised a third set of guidelines – the orthopaedic care guidelines that were created and published by the Duchenne Care UK programme that we fund …
Landmark day for Duchenne as Givinostat approved for use in England
On a landmark day for the Duchenne muscular dystrophy community, we are delighted to share that the National Institute for Health and Care Excellence (NICE) has recommended the treatment givinostat (brand name Duvyzat) for use on the NHS in England. In final draft...
Solid doses first patient on Phase 3 trial
Solid Biosciences announced that the first participant has been dosed in the Phase 3 Impact Duchenne clinical trial…
Duchenne Care UK launches psychosocial guidelines

The UK’s first psychosocial clinical recommendations for Duchenne muscular dystrophy have been published by the Duchenne Care UK psychosocial working group …
Solid announces positive clinical update
Solid Biosciences has announced a positive clinical update on the SGT-003 gene therapy programme
Duchenne Care UK strives for best care for all at national meeting
At the third national meeting for Duchenne Care UK, more than 80 healthcare professionals and patient representatives convened to review the latest developments in care standards, and attend workshops to discuss best practice for the next phase of this groundbreaking national programme …
DMD Care UK respiratory guideline recognised by NICE
The Duchenne Research Fund is delighted to share that NICE has recognised the respiratory care guidelines that were created and published by the DMD Care UK programme that we fund …
New Duchenne treatment approved for use in Scotland
Scottish Medicines Consortium (SMC) has approved the treatment givinostat for use on the NHS in Scotland, for children aged 6+ who are still able to walk. It is currently under review by the UK’s National Institute for Health and Care Excellence (NICE) as to whether it will be approved for use in NHS England …
World Muscle Society awards 2025 DRF prize
The World Muscle Society has awarded the Duchenne Research Fund prize at the annual WMS international congress to Luca Bello from the University of Padua …
Solid shares update on Inspire Duchenne clinical trial
Solid Biosciences has released an update on its Inspire Duchenne clinical trial. The Phase 1/2, open-label study has now dosed 23 patients, and expects to have dosed 30 by early 2026 …
DMD Care UK cardiac guideline recognised by NICE
On World Duchenne Awareness Day 2025, the Duchenne Research Fund is delighted to share that NICE has recognised the cardiac care guidelines that were created and published by the DMD Care UK programme that we fund …
DMD Care UK publishes annual meeting report
DMD Care UK has published a report following its national meeting earlier this year, sharing insights into the success of its workshops and knowledge sharing. More than 80 clinical professionals attended in person, and there were more than 170 dial-ins …
Duchenne community campaigns for givinostat

To the disappointment of the Duchenne community, NICE has announced it will seek further guidance on whether new treatment givinostat should be made routinely available on the NHS …
Update on gene therapy Elevidys
Earlier this month the US Food and Drug Administration (FDA) requested that Sarepta Therapeutics place Elevidys clinical trials on hold, due to safety concerns …
DMD Care UK national meeting drives improved care
At the second national meeting for DMD Care UK, more than 80 healthcare professionals and patient representatives attended workshops and held discussions around the progress made so far …
Solid reports positive clinical trial data
Solid Biosciences has shared positive clinical data for the first three patients in its Inspire Duchenne clinical trial …
NICE approves DRF-funded treatment for Duchenne
The National Institute for Health and Care Excellence (NICE) has approved vamorolone for use on the NHS to treat Duchenne muscular dystrophy. Vamorolone, also known by the brand name Agamree, will be available to treat people with Duchenne aged 4 and older. The Duchenne Research Fund has helped nurture the development of vamorolone for ten years in a ground-breaking example of venture philanthropy …
John Walton Muscular Dystrophy Research Centre marks 10 years
We were invited to join the celebrations for the John Walton Muscular Dystrophy Research Centre’s 10th anniversary in Newcastle …
Solid expands gene therapy trial
We are pleased to share that Solid Biosciences has seen encouraging early results so far in the clinical trial of its next-generation gene therapy, SGT-003.
World Muscle Society awards 2024 DRF prize

The World Muscle Society has awarded the Duchenne Research Fund prize at the annual WMS international congress, supporting a talented researcher in the Duchenne arena …
Solid begins dosing next-generation gene therapy

We are pleased to share that Solid Biosciences has begun dosing patients in the Phase I/II clinical study of its next-generation gene therapy, SGT-003. The study, INSPIRE DUCHENNE, is ongoing at two sites in the US …
FDA expands approval for gene therapy Elevidys
The US Food and Drug Adminisatration has announced it has expanded the approval of Sarepta Therapeutics’ gene therapy, known as Elevidys, for the treatment of ambulatory and non-ambulatory people with Duchenne aged 4 and over …
Pfizer provides update on gene therapy trial
Pfizer has announced that its mini-dystrophin gene therapy has not met its primary or secondary endpoints.
DMD Care UK explores next steps for patient care
On 29th February, Rare Disease Day, we were pleased to be part of the 2024 national meeting for DMD Care UK. More than 130 clinicians and 25 patient representatives are now involved in DMD Care UK …
DMD Care UK launches new respiratory guidance

We are pleased to share that DMD Care UK’s new respiratory guidance has been endorsed by the British Thoracic Society and published in Thorax, an international peer-reviewed medical journal with a respiratory focus. It is published by the BMJ Group on behalf of the British Thoracic Society …
Vamorolone approved in the UK

The Duchenne Reserach Fund is delighted to share that the MHRA has approved vamorolone (sold under the brand name AGAMREE) for the treatment of Duchenne in patients aged 4 years and older. It is not yet available on the NHS …
Vamorolone approved in the EU

The European Medicines Agency (EMA) has granted marketing authorisation for vamorolone (sold under the brand name AGAMREE) for the treatment of Duchenne in patients aged 4 years and older …
Sarepta announces gene therapy results
Pharmaceutical company Sarepta has announced results of Part 1 of its Phase 3 Embark gene therapy trial for Duchenne, sharing that it did not meet its primary endpoint …
Vamorolone approved in the US
The US FDA has approved Vamorolone for the treatment of Duchenne muscular dystrophy in children and adults aged 2 and over. It will be sold under the brand name Agamree …
First ever treatment for all Duchenne patients recommended for approval

The EMA (European Medicines Agency) has recommended the approval of Vamorolone – the first ever treatment for all patients with Duchenne …
World Muscle Society awards 2023 DRF prize
The World Muscle Society has once again awarded the Duchenne Research Fund prize at the annual WMS international congress, supporting a talented researcher in the Duchenne arena.
FDA approves first gene therapy for Duchenne
The FDA has granted accelerated approval for the gene therapy treatment SRP-9001. This is the first time a gene therapy for Duchenne has been approved anywhere in the world …
Catalysts Pharmaceuticals to distribute vamorolone in North America
Santhera Pharmaceuticals, which manufacturers vamorolone, has announced it has licensed vamorolone to Catalyst Pharmaceuticals in North America
DRF highlights psychosocial research at parent information day

The DRF was pleased to participate in Duchenne UK’s latest parent information day, held in March in central London.
See the smart suit that is changing children’s lives
On Rare Disease Day, watch Eli Crossley, son of our friend and Duchenne UK co-founder Emily, as he talks about – and demonstrates – the amazing technological developments that are being trialled for children with Duchenne muscular dystrophy. The ‘smart suit’ aims to help children who are losing upper body function in still continuing to use their arms.
Psychosocial project now under way with DRF funding
At The Duchenne Research Fund, we are proud to support the DMD Care UK Psychosocial programme and help further research in a vital but under-explored aspect of living with Duchenne.
DRF co-founder raises £15,000 in first marathon

We are so proud of our co-founder, Doron Rosenfeld, who has completed his first ever marathon in 4 hours 43 minutes.
DRF-funded KineDMD study published in Nature Medicine and featured on BBC

We are delighted that the ground-breaking KineDMD activity monitoring study we funded has been published in the prestigious scientific journal Nature Medicine, and covered by the BBC …
Solid completes acquisition of AavantiBio

We are pleased to share that Solid Biosciences has completed its acquisition of gene therapy company AavantiBio in a pivotal moment for the company …
Parents urged to read new cardiac recommendations for Duchenne
DMD Care UK’s new cardiac care recommendations have been published in the BMJ Open Heart journal. All Duchenne parents and caregivers are being urged to read the new guidance and share with their networks, as protecting the heart early is crucial to preventing unnecessary deaths. Leading cardiologists, Duchenne specialists and patients and caregivers came together …
Solid to acquire AavantiBio and focus on next-generation gene therapy candidate
Solid Biosciences has announced its entry into a definitive merger agreement to acquire AavantiBio, to create a genetic medicines company focused on neuromuscular and cardiac rare diseases, maintaining a strong focus on Duchenne …
DRF-funded physio role to become permanent at GOSH

We are delighted to share that Great Ormond Street Hospital Trust has agreed to make permanent a physiotherapist role that the Duchenne Research Fund has funded for the past few years …
Psychological and psychiatric support put in place for Duchenne patients and families

Dedicated specialist support for Duchenne muscular dystrophy (DMD) patients and families’ mental health and wellbeing will soon be more readily available, as part of the DMD Care UK project.
DMD Hub launches Central Recruitment Pilot Project
The DMD Hub is launching the Central Recritment Pilot Project, aiming to create a database of families interested in take part in clinical trials …
Solid data shows improved motor and lung function
We are pleased to share Solid Biosciences' latest update on the IGNITE DMD gene therapy clinical trial. Data after two years suggests that patients' motor function and lung function are improved compared to the declines that would be expected without treatment. The...
Emergency app launched for Duchenne
An ‘In Case of Emergency’ app has been launched for Duchenne patients and their families, as part of the DMD Care UK project …
DRF-funded project aims to screen for neurobehavioural issues

The Duchenne Research Fund is pleased to share an update on the PPMD project we have funded evaluating neurobehavioural and psychosocial issues in Duchenne. Analysis of the data is ongoing, but key findings include …
Five-year grant to Dr Michela Guglieri: outcome report
We are delighted to report the outcomes of our grant for a Clinical Trials Lectureship. The grant, which was supported by a consortium of seven UK charities …
DMD Care UK: Psychosocial Programme now recruiting
We are pleased to announce that the University of Newcastle is now recruiting for a clinical psychologist to work with Duchenne patients …
Santhera and ReveraGen share latest vamorolone study results
We are pleased to share the announcement from Santhera Pharmaceuticals and ReveraGen BioPharma of new topline results after completion of the VISION-DMD study at week 48 …
DRF awards £640,000 for vital psychosocial project

The Duchenne Research Fund is delighted to announce that we are awarding a £640,000 grant to fund vital psychosocial care and research as part of Duchenne UK’s DMD Care UK programme.
#TeamDRF raise £28,000 in London Marathon
Congratulations to #TeamDRF's Adam, Benji, Charles and Yossi who completed the London Marathon on Sunday 3rd October 2021, raising more than £28,000 for the Duchenne Research Fund. The annual event is the largest marathon in the UK, attracting around 40,000...
DRF-funded drug shows success in clinical trial

We are pleased to share that Vamorolone, an alternative medicine to corticosteroids, has shown positive results in a Phase 2 Study …
Watch the highlights of An Evening with the DRF
Watch the highlights of Gavriel Rosenfeld in conversation with Dr Ronni Cohn at our virtual Evening with the Duchenne Research Fund. More than 500 people watched our virtual event to hear Gavriel talk about living with Duchenne, mental health, juggling school and hospital visits, and more …
Gavriel Rosenfeld talks to Dr Ronni Cohn about living with Duchenne
On Wednesday 17th March the Duchenne Research Fund hosted a virtual evening giving supporters an update on ongoing research funded by the charity. We were so thrilled that Gavriel Rosenfeld, the son of the DRF’s founders Kerry & Doron Rosenfeld, joined the virtual event …
DRF funds PPMD neurobehavioural research

We have awarded an £80,000 grant to Parent Project Muscular Dystrophy (PPMD) to support its research into neurobehavioral issues in Duchenne – focusing on key areas such as learning, behaviour, depression and anxiety …
DRF funds Duchenne clinic at Great Ormond Street

We are pleased to share that we have awarded a grant of £35,000 to Great Ormond Street Hospital to establish a dedicated clinic for children who are non-ambulant (no longer able to walk). The grant supports the post of Senior Physiotherapist Nicola Burnett and has enabled more than 80 patients to be seen …
DRF grants £40,000 to DMD Care UK project
We have awarded £40,000 to the newly launched DMD Care UK, partnering with the project’s founders Duchenne UK and Joining Jack. Together our three charities will invest £130,000 in the nationwide initiative that aims to ensure the best care for everyone living with Duchenne in the UK …
Run the London Marathon with DRF

We are pleased to announce that the Duchenne Research Fund has places available for the 2021 Virgin Money London Marathon, which is due to take place on Sunday 3rd October …
ReveraGen receives $3.3m NIH grant for Vamorolone

ReveraGen BioPharma has received a $3.3 million grant from the NIH – the US National Institutes of Health – for their work on Vamorolone …
Solid announces collaboration with Ultragenyx

Ultragenyx Pharmaceutical and Solid Biosciences have announced a strategic collaborations and license agreement to focus on the development and commercialisation of new gene therapies for Duchenne …
Two-year Vamorolone study completed

Santhera Pharmaceuticals has announced that partner ReveraGen Biopharma has completed a long-term, open-label extension study of 24 months duration with Vamorolone in patients with Duchenne…
Update on Ignite DMD from Solid Biosciences
Solid Biosciences has issued an update on IGNITE DMD, the Phase I/II clinical study with its microdystrophin gene therapy, SGT-001.
DRF-funded research featured on ITV’s Little Heroes
We are so proud that the family of our founders, Kerry and Doron Rosenfeld, starred in Paul O’Grady’s Little Heroes on ITV …
DRF-funded Imperial College AI study extended

The Duchenne Research Fund is pleased to share that the ground-breaking KineDMD activity monitoring study at Imperial College London/GOSH has been extended into 2021…
Cyclists take on Prudential ride to raise funds for DRF
Congratulations to the #TeamDRF cyclists who once again took on the Prudential RideLondon-Surrey, and raised more than £5,000…
Martyn and Jessica trek Snowdonia to raise funds for DRF
Congratulations to Jessica and Martyn Jacobs who trekked Snowdownia to support the Duchenne Research Fund …
Sam and Avi run marathon for DRF
Thank you to Sam Baum, Avi Mocton and Alex Klinger who raised funds for the Duchenne Research Fund …
DRF funds University of Florida research to tackle gene therapy immunity challenges
The Duchenne Research Fund has awarded a grant to Dr Barry Byrne and Dr Manuela Corti’s team at the University of Florida, whose vital work focuses on overcoming immunological challenges to ensure all boys and young men can benefit from gene therapy treatments for...
DRF Head of Scientific Advisory Board becomes hospital President and CEO
We are delighted to share the news that Dr Ronald Cohn, the head of the DRF’s Scientific Advisory Board, has been made President and CEO of the Hospital for Sick Children …
Solid Biosciences announces preliminary gene therapy clinical trial results and intention to dose escalate

Solid Biosciences has announced preliminary data from its gene therapy clinical trial, IGNITE DMD …
DRF funding helps double number of children on neuromuscular clinical trials at GOSH
We are pleased to share a report from Great Ormond Street Hospital (GOSH) about the positive impact of the clinical staff posts that we helped to fund at the hospital, together with Duchenne UK, Harrison’s Fund and the Great Ormond Street Charity …
DRF co-founders honoured by Prime Minster’s Office
The Duchenne Research Fund’s co-founders Kerry and Doron Rosenfeld are honoured to have received the Prime Minister’s Points of Light award …
Lauren skydives in memory of brother Charlie
Thank you to Lauren Halsey who raised funds for the DRF by skydiving …
DRF funds CRISPR research to correct Duchenne mutations
The Duchenne Research Fund has awarded a £200,000 grant to the team at the Hospital for Sick Children in Toronto, Canada (‘Sick Kids’), who are working on using CRISPR/Cas9 technology…
#TeamDRF raises £30,000 in Prudential cycle ride
Congratulations to the #TeamDRF cyclists who took on the Prudential RideLondon-Surrey on Sunday 29 July in treacherous conditions and raised more than £30,000…
Vamorolone shows improvements in strength and endurance in boys with Duchenne
We are pleased to share an update from ReveraGen about its Vamorolone clinical trial. Vamorolone is an alternative treatment to existing steroids that aims to maximise the benefits while reducing the side effects. In 2014, The Duchenne Research Fund helped fund the...
Gene therapy for Duchenne: latest news
Five years ago we identified gene therapy as a viable treatment for Duchenne. Today we are reflecting on the exciting and inspiring events of the past week in the gene therapy arena which are now bringing hope and cautious optimism to the Duchenne community. We have...
Solid Biosciences clear to resume IGNITE DMD
Message from Solid Biosciences: "We’re pleased to share with you that the FDA has lifted the clinical hold on IGNITE DMD, our clinical trial investigating SGT-001 as a potential treatment for Duchenne muscular dystrophy (DMD). SGT-001 is a microdystrophin gene...
DRF-funded Imperial College AI study aims to accelerate Duchenne research and trials
The Duchenne Research Fund recently shared the news that we are supporting the KineDMD study - Dr Aldo Faisal's ground-breaking artificial intelligence study at Imperial College London, in collaboration with Great Ormond Street Hospital, which aims to accelerate...
DRF funds Newcastle refurbishment
On Wednesday 27 September 2017, the newly refurbished paediatric area in the Clinical Research Facility at Newcastle Royal Victoria Infirmary was officially opened by Professor Mark Walker and Dr Michela Guglieri.
Duchenne Hub day tackles clinical trial access
The Duchenne Research Fund was delighted to participate in the Duchenne Hub information day held on 18 September 2017 at Alder Hey Children’s Hospital in Liverpool.
Solid Biosciences news
Solid Biosciences recently reported that it has raised up to $50 million which will enable the biotech to continue to advance its programs for Duchenne muscular dystrophy, including development of a microdystrophin gene. We are forever grateful to our incredible...
DRF raises £140,000 in Yorkshire Three Peaks challenge

On Sunday 9th July 2017, 43 intrepid hikers from London, Manchester and New York donned their walking boots and waterproofs and braved the challenging Yorkshire Three Peaks: a 40km hike with 1600 metres of ascent in a target time of 12 hours, raising money to support vital Duchenne Research Fund projects …
Vamorolone receives Fast Track designation from FDA
We’re pleased to share news from ReveraGen, the company developing the novel steroid alternative Vamorolone (previously called VBP15), that their drug has received Fast Track designation from the FDA, which will speed up the review of Vamorolone.
DRF supports projects to tackle fibrosis and enhance drug development
The Duchenne Research Fund is delighted to share the details of the exciting new projects we are funding thanks to donors’ generosity and support, including tackling fibrosis and inflammation, and developing non-invasive biomarkers.
ReveraGen BioPharma licenses option to develop Vamorolone with Actelion
We’re sharing news that ReveraGen BioPharma has licensed an option to develop Vamorolone with Actelion Ltd.
Vamorolone is the first in-human steroid like compound that has shown in animal models to have many of the benefits of corticosteroids, without the many side effects …
DRF marks World Duchenne Awareness Day
On Wednesday 7 September 2016, the Duchenne Research Fund team, together with the charity’s co-founder Kerry Rosenfeld and her son Gavriel, marked World Duchenne Awareness Day.
The theme for 2016 is early diagnosis: focusing on how identifying and communicating early signs of Duchenne muscular dystrophy …
Duchenne patients recruited for steroid replacement study
We are delighted to announce that ReveraGen BioPharma, the company developing a steroid replacement for Duchenne muscular dystrophy, has begun recruiting patients for its Phase 2a open label study. The trial will be recruiting patients who haven’t yet started steroids, between the ages of 4 and 7 …
Ten posts in place to support UK clinical trial capacity
Today we are announcing that TEN posts have been filled out of sixteen clinical posts to support clinical trial development for Duchenne. The posts are part of a £1.2m investment by eight patient organisations under the Newcastle Plan.
DRF raises £1.2 million to help beat Duchenne
The Duchenne Research Fund raised £1.2 million at its ‘The Time Is Now’ Gala Dinner on 5 May at the Lancaster London Hotel to help find a cure for Duchenne muscular dystrophy …
DRF-funded drug development programme receives further £4.6 million
The Duchenne Research Fund, the Duchenne Children’s Trust and Joining Jack and are delighted with the news from the John Walton Muscular Dystrophy Research Centre that they have received £4.26 million in European funding for a Phase II clinical trial for Vamorolone – also known as VBP15 – an anti-inflammatory drug …
DRF’s Chief Scientific Advisor first to correct Duchenne genetic error with cutting edge CRISPR technology

Dr Ronald Cohn, who leads the Duchenne Research Fund’s Scientific Advisory Board, has become the first ever researcher to successfully correct one of the mutations that causes Duchenne muscular dystrophy, working on cells in his laboratory at the Centre for Genetic Medicine at Toronto’s Hospital for Sick Children …
Dog with dystrophin mutation saved from Duchenne
DRF-funded research was published this week in Cell, one of the world’s most prestigious scientific journals, analysing why two golden retrievers showed no severe symptoms of Duchenne muscular dystrophy and unexpectedly lived a normal lifespan despite being born with the genetic mutation that causes Duchenne. It is now thought that the results could open up new avenues for possible treatments …
DRF’s funding of Solid GT leads to $42.5 million investment
We are thrilled that the money raised through the Duchenne Research Fund’s 2013 dinner and donations since then have enabled us to seed fund the incredible Solid GT project, which has today received industry investment (read the press release below). While gene therapy is an exciting piece of the puzzle for beating Duchenne for all boys, it is now more critical than ever that we continue to raise vital funds to push Duchenne therapies into clinical trial as quickly and safely as possible and to get them to our boys NOW.
Albourne raises £155,000 for DRF
We are immensely grateful to Albourne Partners and their supporters for raising more than £155,000 for our projects at their incredible performance of ‘The Importance of Being Lewis’ on 7 October. The event was held to honour the memory of Jacques Joubert (1992-2015) who had Duchenne …
Gene therapy breakthrough in muscular dystrophy dogs
The Duchenne Research Fund is incredibly proud of Dr Dongsheng Duan – an important Scientific Advisory Board member of Solid GT, a gene therapy programme pioneered by Solid Biosciences and that we helped to fund. Dr Duan’s latest gene therapy work on muscular dystrophy dogs is set to significantly impact 100% of the Duchenne population.
He also recently received a five-year, $3 million grant from the NIH (National Institutes of Health) …
DRF-funded study shows encouraging results in combating muscle-wasting
Professor Dame Kay Davies (University of Oxford) and her group have recently published encouraging results of a study to test new second-generation compounds to increase the level of utrophin protein as a treatment for boys and men with Duchenne and Becker muscular dystrophies.
Utrophin is a protein that occurs naturally in the body. It is usually only made in large amounts during development in the womb and is only present in small amounts in adults. Utrophin is very similar to dystrophin in its structure and previous research has shown that it can compensate for the lack of dystrophin in animal models of Duchenne muscular dystrophy …
Newcastle Plan aims to boost UK clinical trial capacity for Duchenne
Last month the Duchenne Research Fund participated in the UK National Workshop on Duchenne Muscular Dystrophy Clinical Trial Capacity at Newcastle University, hosted by TREAT-NMD. The landmark meeting brought together 75 representatives from patient organisations, pharmaceutical companies, the National Institute for Health Research and a wide range of clinicians, to discuss the challenges and solutions to increase clinical trial capacity in the UK …
Our mission
Our impact
Your help
Your generosity has funded millions of pounds worth of ground-breaking research.
And there is still work to do.
















